{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:18:20Z","timestamp":1790759900226,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA087497-20"],"award-info":[{"award-number":["P01CA087497-20"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1038\/s41418-022-00980-7","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T10:12:26Z","timestamp":1649153546000},"page":"938-945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein"],"prefix":"10.1038","volume":"29","author":[{"given":"David","family":"Hoyos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-6387","authenticated-orcid":false,"given":"Arnold J.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"980_CR1","doi-asserted-by":"publisher","unstructured":"Levine AJ p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. (2020). https:\/\/doi.org\/10.1038\/s41568-020-0262-1.","DOI":"10.1038\/s41568-020-0262-1"},{"key":"980_CR2","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1101\/gad.8.10.1235","volume":"8","author":"J Lin","year":"1994","unstructured":"Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 1994;8:1235\u20131246.","journal-title":"Genes Dev"},{"key":"980_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ceb.2017.11.005","volume":"51","author":"SS Mello","year":"2018","unstructured":"Mello SS, Attardi LD. Deciphering p53 signaling in tumor suppression. Curr Opin Cell Biol. 2018;51:65\u201372. https:\/\/doi.org\/10.1016\/j.ceb.2017.11.005.","journal-title":"Curr Opin Cell Biol"},{"key":"980_CR4","doi-asserted-by":"publisher","first-page":"15335","DOI":"10.1073\/pnas.93.26.15335","volume":"93","author":"KK Walker","year":"1996","unstructured":"Walker KK, Levine AJ. Identification of a novel p53 functional domain which is necessary for efficient growth suppression. Proc Natl Acad Sci, USA. 1996;93:15335\u201315340.","journal-title":"Proc Natl Acad Sci, USA"},{"key":"980_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.onc.1205015","volume":"21","author":"N Baptiste","year":"2002","unstructured":"Baptiste N, Friedlander P, Chen X, Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 2002;21:9\u201321.","journal-title":"Oncogene"},{"key":"980_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cdd.2017.180","volume":"25","author":"EH Baugh","year":"2018","unstructured":"Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;25:154\u2013160.","journal-title":"Cell Death Differ"},{"key":"980_CR7","doi-asserted-by":"publisher","first-page":"14987","DOI":"10.1126\/science.7878469","volume":"267","author":"PD Jeffrey","year":"1995","unstructured":"Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 1995;267:14987\u20131502.","journal-title":"Science"},{"key":"980_CR8","doi-asserted-by":"publisher","first-page":"9822","DOI":"10.1073\/pnas.1610387113","volume":"113","author":"J Zhu","year":"2016","unstructured":"Zhu J, Dou Z, Sammons MA, Levine AJ, Berger SL. Lysine methylation represses p53 activity in teratocarcinoma cancer cells. Proc Natl Acad Sci USA. 2016;113:9822\u20139827. https:\/\/doi.org\/10.1073\/pnas.1610387113.","journal-title":"Proc Natl Acad Sci USA"},{"key":"980_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000154228","volume":"44","author":"G Beckman","year":"1994","unstructured":"Beckman G, Birgander R, Sj\u00e4lander A, Saha N, Holmberg PA, Kivel\u00e4 A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994;44:266\u201370. https:\/\/doi.org\/10.1159\/000154228.","journal-title":"Hum Hered"},{"key":"980_CR10","doi-asserted-by":"publisher","first-page":"a026187","DOI":"10.1101\/cshperspect.a026187","volume":"7","author":"T Guha","year":"2017","unstructured":"Guha T, Malkin D. Inherited TP53 mutations and the li-fraumeni syndrome. Cold Spring Harb Perspect Med. 2017;7:a026187 https:\/\/doi.org\/10.1101\/cshperspect.a026187.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"980_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ccr.2006.03.014","volume":"9","author":"F Toledo","year":"2006","unstructured":"Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell. 2006;9:273\u2013285.","journal-title":"Cancer Cell"},{"key":"980_CR12","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1128\/MCB.21.12.3974-3985.2001","volume":"21","author":"JT Zilfou","year":"2001","unstructured":"Zilfou JT, Hoffman WH, Sank M, George DL, Murphy M. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol Cell Biol. 2001;21:3974\u201385. https:\/\/doi.org\/10.1128\/MCB.21.12.3974-3985.2001.","journal-title":"Mol Cell Biol"},{"key":"980_CR13","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1074\/jbc.M008879200","volume":"276.6","author":"M Berger","year":"2001","unstructured":"Berger M, Sionov RV, Levine AJ, Haupt Y. A role for the polyproline domain of p53 in its regulation by Mdm2. J Biol Chem. 2001;276.6:3785\u20133790.","journal-title":"J Biol Chem"},{"key":"980_CR14","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.1158\/1078-0432.CCR-05-0507","volume":"11","author":"Y Xu","year":"2005","unstructured":"Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, et al. Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Canc Res. 2005;11:7328\u20137333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0507","journal-title":"Clin Canc Res"},{"key":"980_CR15","doi-asserted-by":"publisher","first-page":"15532","DOI":"10.1073\/pnas.1411746111","volume":"111","author":"MG Lee","year":"2014","unstructured":"Lee MG, Han J, Jeong SI, Her NG, Lee JH, Ha TK, et al. XAF1 directs apoptotic switch of p53 signaling through activation of HIPK2 and ZNF313. Proc Natl Acad Sci USA 2014;111:15532\u20137. https:\/\/doi.org\/10.1073\/pnas.1411746111.","journal-title":"Proc Natl Acad Sci USA"},{"key":"980_CR16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/jmcb\/mjz052","volume":"11","author":"T Barnoud","year":"2019","unstructured":"Barnoud T, Parris JLD, Murphy M. Common genetic variants in the Tp53 pathway and their impact on cancer. Jour Mol Cell Biol. 2019;11:578\u2013585.","journal-title":"Jour Mol Cell Biol"},{"key":"980_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ajhg.2009.03.009","volume":"84","author":"H Shi","year":"2009","unstructured":"Shi H, Tan SJ, Zhong H, Hu W, Levine A, Xiao CJ, et al. Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet. 2009;84:534\u201341. https:\/\/doi.org\/10.1016\/j.ajhg.2009.03.009.","journal-title":"Am J Hum Genet"},{"key":"980_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.cell.2013.09.017","volume":"155","author":"J Zeron-Medina","year":"2013","unstructured":"Zeron-Medina J, Wang X, Repapi E, Campbell MR, Su D, Castro-Giner F, et al. A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection. Cell. 2013;155:410\u201322. https:\/\/doi.org\/10.1016\/j.cell.2013.09.017.","journal-title":"Cell"},{"key":"980_CR19","doi-asserted-by":"publisher","first-page":"eaba3231","DOI":"10.1126\/sciadv.aba3231","volume":"6","author":"EM Pinto","year":"2020","unstructured":"Pinto EM, Figueiredo BC, Chen W, Galvao HCR, Formiga MN, Fragoso MCBV, et al. XAF1 as a modifier of p53 function and cancer susceptibility. Sci Adv. 2020;6:eaba3231 https:\/\/doi.org\/10.1126\/sciadv.aba3231.","journal-title":"Sci Adv"},{"key":"980_CR20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","volume":"37","author":"L Bouaoun","year":"2016","unstructured":"Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37:865\u201376. https:\/\/doi.org\/10.1002\/humu.23035.","journal-title":"Hum Mutat"},{"key":"980_CR21","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMp1607591","volume":"375","author":"RL Grossman","year":"2016","unstructured":"Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, et al. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;375:1109\u201312. https:\/\/doi.org\/10.1056\/NEJMp1607591.","journal-title":"N Engl J Med"},{"key":"980_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703\u2013713. https:\/\/doi.org\/10.1038\/nm.4333. Erratum in: Nat Med 23(8):1004 (2017).","journal-title":"Nat Med"},{"key":"980_CR23","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"AACR Project GENIE Consortium.","year":"2017","unstructured":"AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7:818\u2013831. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0151.","journal-title":"Cancer Discov"},{"key":"980_CR24","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941\u20137.","journal-title":"Nucleic Acids Res"},{"key":"980_CR25","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1431692100","volume":"100","author":"S Kato","year":"2003","unstructured":"Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function\u2013structure and function\u2013mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci. 2003;100:8424\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"980_CR26","first-page":"5520","volume":"51","author":"Y Murakami","year":"1991","unstructured":"Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Canc Res. 1991;51:5520\u20135.","journal-title":"Canc Res"},{"key":"980_CR27","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1182\/blood.V85.9.2546.bloodjournal8592546","volume":"85","author":"M Kawamura","year":"1995","unstructured":"Kawamura M, Kikuchi A, Kobayashi S, Hanada R, Yamamoto K, Horibe K, et al. Mutations of the p53 and ras genes in childhood t (1; 19)-acute lymphoblastic leukemia. Blood. 1995;85:2546\u201352.","journal-title":"Blood"},{"key":"980_CR28","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199205143262001","volume":"326","author":"J Toguchida","year":"1992","unstructured":"Toguchida J, Yamaguchi T, Dayton SH, Beaughamp RL, Herrera GE, Ishizaki K, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med. 1992;326:1301\u20138.","journal-title":"N Engl J Med"},{"key":"980_CR29","doi-asserted-by":"publisher","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","volume":"49","author":"UniProt Consortium.","year":"2021","unstructured":"UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021;49:D480\u2013D489.","journal-title":"Nucleic Acids Res"},{"key":"980_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1682","volume":"9","author":"T Toyama","year":"2007","unstructured":"Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 2007;9:R34 https:\/\/doi.org\/10.1186\/bcr1682.","journal-title":"Breast Cancer Res"},{"key":"980_CR31","doi-asserted-by":"publisher","unstructured":"Weng Z, Rickles RJ, Feng S, Richard S, Shaw AS, Schreiber SL et al. Structure-function analysis of SH3 domains: SH3 binding specificity altered by single amino acid substitutions. Mol Cell Biol. :5627\u201334 (1995). https:\/\/doi.org\/10.1128\/MCB.15.10.5627.","DOI":"10.1128\/MCB.15.10.5627"},{"key":"980_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jmb.2011.03.047","volume":"409","author":"E Natan","year":"2011","unstructured":"Natan E, Baloglu C, Pagel K, Freund SM, Morgner N, Robinson CV, et al. Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer. J Mol Bio. 2011;409:358\u201368.","journal-title":"J Mol Bio"},{"key":"980_CR33","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1128\/MCB.25.13.5380-5388.2005","volume":"25","author":"M Berger","year":"2005","unstructured":"Berger M, Stahl N, Del Sal G, Haupt Y. Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol Cell Biol. 2005;25:5380\u20138. https:\/\/doi.org\/10.1128\/MCB.25.13.5380-5388.2005.","journal-title":"Mol Cell Biol"},{"key":"980_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/ncb714","volume":"4","author":"G D\u2019Orazi","year":"2002","unstructured":"D\u2019Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 2002;4:11\u20139. https:\/\/doi.org\/10.1038\/ncb714.","journal-title":"Nat Cell Biol"},{"key":"980_CR35","doi-asserted-by":"publisher","first-page":"8846","DOI":"10.1128\/MCB.23.23.8846-8861.2003","volume":"23","author":"D Dornan","year":"2003","unstructured":"Dornan D, Shimizu H, Burch L, Smith AJ, Hupp TR. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol Cell Biol. 2003;23:8846\u20138861.","journal-title":"Mol Cell Biol"},{"key":"980_CR36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/3590550237","volume":"3","author":"P Liston","year":"2001","unstructured":"Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, et al. Identification of XAF-1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol. 2001;3:128\u2013133. https:\/\/doi.org\/10.1038\/3590550237.","journal-title":"Nat Cell Biol"},{"key":"980_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101. https:\/\/doi.org\/10.1038\/s41586-020-1943-3.","journal-title":"Nature"},{"key":"980_CR38","doi-asserted-by":"publisher","first-page":"i216","DOI":"10.1093\/bioinformatics\/bth901","volume":"20","author":"G Lunter","year":"2004","unstructured":"Lunter G, Hein J. A nucleotide substitution model with nearest-neighbour interactions. Bioinformatics. 2004;20:i216\u2013i223.","journal-title":"Bioinformatics"},{"key":"980_CR39","unstructured":"Soria CD, Pacifici M, DiMarco M, Stephen SM & Rondindi C COMBINE: a coalesced mammal database of intrinsic and extrinsic traits, Ecology. 10-1002\/ecy3344."},{"key":"980_CR40","doi-asserted-by":"publisher","first-page":"a001198","DOI":"10.1101\/cshperspect.a001198","volume":"2","author":"VA Belyi","year":"2010","unstructured":"Belyi VA, Ak P, Markert E, Wang H, Hu W, Puzio-Kuter A, et al. The origins and evolution of the P53 family of genes. Cold Spring Harb Perspect Biol. 2010;2:a001198. https:\/\/doi.org\/10.1101\/cshperspect.a001198.","journal-title":"Cold Spring Harb Perspect Biol"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-00980-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-00980-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-00980-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T07:07:08Z","timestamp":1652166428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-022-00980-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["980"],"URL":"https:\/\/doi.org\/10.1038\/s41418-022-00980-7","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"26 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DH has no competing interests. AL is a founder, shareholder, receives fees from, and is a member of the board of directors of PMV pharmaceutical company, which produces small molecules that reactivate mutant p53 proteins. He also chairs the SAB of Janssen Pharmaceutical company and is a member of the board of Meira GTX, a gene therapy company for restoring eye sight. He is also a member of the board of directors of GeneCentric, a RNA seq diagnostic company for cancer treatments. He also receives funding from a grant from the NCI, P01CA087497-20. BG is a founder, and advisor of ROME, a company that explores the role of repetitive DNA sequences in cancers. AL is on the SAB of ROME.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}